



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/43	A1	(11) International Publication Number: WO 91/10444 (43) International Publication Date: 25 July 1991 (25.07.91)
<p>(21) International Application Number: PCT/US91/00074</p> <p>(22) International Filing Date: 4 January 1991 (04.01.91)</p> <p>(30) Priority data: 461,714 8 January 1990 (08.01.90) US</p> <p>(71) Applicant: GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).</p> <p>(72) Inventors: ATTIE, Kenneth, M. ; 326 Carl Street, San Francisco, CA 94117 (US). MATHER, Jennie, P. ; 269 La Prenda Drive, Millbrae, CA 94030 (US).</p> <p>(74) Agents: HASAK, Janet, E. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: METHOD FOR INCREASING FERTILITY IN MALES</p> <p>(57) Abstract</p> <p>A method is provided for increasing fertility in a male mammal exhibiting germinal epithelium failure comprising administering to the mammal an effective amount of activin. Preferably, the administration is to the testis of the mammal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

METHOD FOR INCREASING FERTILITY IN MALES

Field of the Invention

This invention relates to a method for increasing fertility in male mammals having a low sperm count.

5 Description of Related Art

Inhibin is a glycoprotein produced by diverse tissues, including the gonads, pituitary, brain, bone marrow, placenta, and adrenal gland. It was initially identified by its ability to inhibit the secretion of follicle stimulating hormone (FSH) by the pituitary. De Jong and Sharpe, Nature, **263**: 71-72 (1976); Schwartz and Channing, Proc. Natl. Acad. Sci. USA, **74**: 5721-5724 (1977). Such preferential regulation of the gonadotropin secretion has generated a great deal of interest and prompted many laboratories in the past fifty years to attempt to isolate and characterize this substance from extracts of testis, spermatozoa, rete testis fluid, seminal plasma, and ovarian follicular fluid using various bioassays. Rivier *et al.*, Biochem. Biophys. Res. Commun., **133**: 120 (1985); Ling *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 7217 (1985); Fukuda *et al.*, Mol. Cell Endocrinol., **44**: 55 (1985). The structure of inhibin, characterized from several species, consists of two disulfide-linked subunits: an α and either a β_A or a β_B chain.

After the identification of inhibin, activin was shown to exist in follicular fluid as a naturally occurring substance. Activin was found to be capable of stimulating FSH release by rat anterior pituitary cells. Vale *et al.*, Nature, **321**: 776-779 (1986); Ling *et al.*, Nature, **321**: 779-782 (1986). Activin consists of a homodimer or heterodimer of inhibin β subunits, which may be β_A or β_B subunits. Vale *et al.*, Recent Prog. Horm. Res., **44**: 1-34 (1988). There is 95-100% amino acid conservation of β subunits among human, porcine, bovine, and rat activins. The β_A and β_B subunits within a given species are about 64-70% homologous. The activin β_A and β_B homodimers ("Activin A" and "Activin B," respectively) have been identified in follicular fluid, and both molecules have been cloned and their genes expressed. Mason *et al.*, Biochem. Biophys. Res. Commun., **135**: 957 (1986); EP Pub. No. 222,491 published May 20, 1987; Mason *et al.*, Molecular Endocrinol., **3**: 1352-1358 (1989). The complete sequence of the β_B subunit is published in Sero Symposium Publications, entitled "Inhibin- Non-Steroidal Regulation of Follicle Stimulating Hormone Secretion", eds. H.G. Burger *et al.*, abstract by A.J. Mason *et al.*, vol. 42, pp. 77-88 (Raven Press: New York 1987), entitled "Human Inhibin and Activin: Structure and Recombinant Expression in Mammalian Cells."

Both Activin A and Activin AB, but thus far not Activin B, have been isolated from natural sources. Activin mRNA (β_A and β_B subunits), bioactivity, and immunoactivity have been reported to be produced by testicular Leydig cells from immature rat and pig. Lee *et al.*, Science, **243**: 396-398 (1989); Lee *et al.*, in Sero Symposium Publications, entitled "The Molecular and Cellular Endocrinology of the Testis," Cooke and Sharpe, eds., Vol. 50 (Raven

-2-

Press: New York, 1988), p. 21-27. Activin A has been found recently to have erythropoietic-stimulating activity as well as FSH-releasing activity. See EP Publ. No. 210,461 published February 4, 1987 (where the protein is called BUF-3), Eto *et al.*, Biochem. Biophys. Res. Commun., 142: 1095-1103 (1987) and Murata *et al.*, Proc. Natl. Acad. Sci. U.S.A., 85:
5 2434-2438 (1988) (where the activin is called EDF), and Yu *et al.*, Nature, 330: 765-767 (1987) (where the activin is called FRP). In these systems, inhibin antagonized the actions of activin.

A protein known as follicle or follicular regulatory protein having a molecular weight of 12,00 to 15,000 is found to inhibit aromatase levels, modulate the formation of mature
10 ova substantially independently of steroidal sex hormones, and reduce fertility in the male rat by systemic treatment. It does not directly affect the gonadotropin output of the pituitary. See U.S. Pat. No. 4,734,398; Tsutsumi *et al.*, Fertil. Steril., 47: 689 (1987); Lew *et al.*, Obstet. and Gynecol., 70: 157-162 (1987); diZerega *et al.*, Meiotic Inhibition: Molecular Control of Meiosis (Alan R. Liss, Inc., 1988), p. 201-226; diZerega *et al.*, J. Steroid
15 Biochem., 27: 375-383 (1987); Montz *et al.*, Am. J. Obstet. Gynecol., 436-441 (Feb. 15, 1984); Ahmad *et al.*, the Anatomical Record, 224: 508-513 (1989). This protein, also named FRP, has been purified and partially sequenced, and is not related in any way to the FSH-releasing protein known as activin, referred to as FRP by the Salk researchers in their early work.

20 Recently, the expression of inhibin subunits, each encoded by a separate gene, was demonstrated in several tissues in addition to ovary and testis. Inhibin α , β_A , and β_B mRNAs were detected in placental, pituitary, adrenal, bone marrow, kidney, spinal cord, and brain tissues. Meunier *et al.*, Proc. Natl. Acad. Sci. USA, 85: 247 (1988). The expression of the inhibin subunit mRNAs varied by several-fold in a tissue-specific manner, suggesting different
25 functions for these proteins depending on their pattern of association and their site of production.

Inhibin and activin are members of a family of growth and differentiation factors. The prototype of this family is transforming growth factor-beta (TGF- β) (Derynck *et al.*, Nature, 316: 701-705 (1985)), which, according to one source, possesses FSH-releasing activity.
30 Ying *et al.*, Biochem. Biophys. Res. Commun., 135: 950-956 (1986). Other members of the TGF- β family include the Mullerian inhibitory substance, the fly decapentaplegic gene complex, and the product of Xenopus Vg-1 mRNA.

In the human, growing preovulatory follicles and corpus luteum secrete inhibin into the circulation in response to FSH stimulation. Lee and Gibson, Aust. J. Biol. Sci., 38: 115-120
35 (1985); McLachlan *et al.*, Fertil. Steril., 48: 1001 (1987). Thus, inhibin-related peptides play important roles in the modulation of gonadal functions via a pituitary feedback loop. In rat primary cultures of testis cells and ovarian thecal-interstitial cells, inhibin has been reported to enhance androgen biosynthesis stimulated by leutinizing hormone (LH), whereas activin

suppresses androgen production. Hsueh *et al.*, Proc. Natl. Acad. Sci. USA, **84**: 5082-5086 (1987). Other workers have been unable to repeat these observations. deKretser and Robertson, Biology of Reproduction, **40**: 33-47 (1989), particularly p. 41. Inhibitory effects of TGF- β on Leydig cell steroidogenesis have also been described. Lin *et al.*, Biochem. Biophys. Res. Commun., **146**: 387 (1987); Fauser and Hsueh, Life Sci., **43**: 1363 (1988); Avallet *et al.*, Biochem. Biophys. Res. Commun., **146**: 575 (1987). In granulosa cells, activin has been reported to inhibit (and TGF- β to enhance) progesterone production. Ignatz and Massague, J. Biol. Chem., **261**: 4337 (1986). In primary cultures of granulosa cells, activin and inhibin as well as TGF- β were found to affect hormone synthesis and secretion, each in a different fashion. Adashi and Resnick, Endocrinology, **119**: 1879 (1986); Ying *et al.*, Biochem. Biophys. Res. Commun., **136**: 969 (1986); Hutchinson *et al.*, Biochem. Biophys. Res. Commun., **146**: 1405 (1987); Mondschein *et al.*, Endocrinology, **123**: 1970 (1988); Feng *et al.*, J. Biol. Chem., **261**: 14167 (1986). These molecules have both positive and negative effects on FSH-dependent granulosa cell function. Carson *et al.*, J. Reprod. Fert., **85**: 735-746 (1989). Also suggested is that individual members of the TGF- β /inhibin gene family regulate ovarian function, not only by direct action on follicle cells, but also indirectly by influencing the production rate of other members of that family. Zhiwen *et al.*, Molecular and Cellular Endocrinology, **58**: 161-166 (1988).

Activin A and inhibin were reported to modulate growth of two gonadal cell lines, suggesting that these proteins may regulate proliferation as well as functions of gonadal cells. Gonzalez-Manchon and Vale, Endocrinology, **125**: 1666-1672 (1989). The secretion of inhibin by the corpus luteum has been proposed to suppress the concentration of FSH in the luteal phase of the cycle and hence the inhibition of follicular development. Baird *et al.*, Ann. N. Y. Acad. Sci., **541**: 153-161 (1988).

A review article postulates that inhibin is at least one of the factors that determines the number of follicles destined to ovulate, and that interference with the action of inhibin might contribute to the regulation of fertility. De Jong, Physiol. Rev., **68**: 555 (1988). Many investigators have speculated that due to its FSH-inhibiting effect, inhibin may be useful in male and female contraception. Sheth and Moodbidri, Adv. Contracept., **2**: 131-139 (1986); Findlay, Fertil. Steril., **46**: 770 (1986); van Dissel-Emiliani *et al.*, Endocrinology, **125**: 1898-1903 (1989); Bhasin *et al.*, Endocrinology, **124**: 987-991 (1989). However, another author doubts that inhibin can inhibit spermatogenesis (citing Bremner *et al.*, J. Clin. Invest., **68**: 1044 (1981)), and states that inhibin might also have some direct stimulatory effects on spermatogenesis. Baker *et al.*, Clin. Reprod. and Fert., **2**: 161-174 (1983).

The distributions of the α , β_A , and β_B subunits of inhibin/activin polypeptides were studied in the testis of rats. It was found that in the rat testis, both Sertoli and interstitial cells produce inhibin/activin subunits, and the α and β subunits are produced by different types of interstitial cells in immature rats. Roberts *et al.*, Endocrinology, **125**: 2350 (1989).

Also it was found that immunoreactive inhibin subunits are present in multiple cells in the testis and that the amounts of immunostainable subunits in the seminiferous epithelium are differentially regulated. Shaha *et al.*, Endocrinology, 125: 1941 (1989).

5 Activin bioactivity has been reported to be secreted by interstitial cells in *in vitro*, while Sertoli cells secrete inhibin or a mixture of inhibin and activin. Lee *et al.*, in Serono Symposium Publications, *supra*; Lee *et al.*, Science, *supra*.

10 Many substances produced in the testes have been shown to regulate testicular function locally. Mather, in Mammalian Cell Culture, ed. J. Mather (Plenum Publishing Corp. 1984), p. 167-193. While inhibin and activin have primarily been considered as feedback regulators of pituitary function, in light of recent data on multiple sites of production and action in the testis, it seems likely that they may also play a role as local regulators of testicular function.

15 Failure to conceive is a complaint that leads as many as one in six married couples to seek medical attention. Of these couples, at least 40% will be discovered to have a male factor deficiency. Approximately 61% of infertile men have hypospermatogenesis on testicular biopsy. These patients have partial germinal epithelium failure and present with oligospermia and normal testosterone levels. The etiology is often idiopathic, but may be associated with antineoplastic agents, cryptorchidism, or varicoceles.

20 In the male, the maturation of immature germ cells into spermatozoa (spermatogenesis) is thought to be regulated by the gonadotropins (LH and especially FSH) and androgens (testosterone). The current treatments for male infertility due to oligospermia are based on this assumption. These include induction of rebound from testosterone or anabolic androgen-induced azospermia; administration of exogenous gonadotropins or gonadotropin releasing hormone; use of clomiphene citrate or tamoxifen to stimulate endogenous gonadotropin secretion; administration of low doses of mesterolone, an oral synthetic androgen; and use of an aromatase inhibitor such as testolactone.

25 No study has conclusively established the benefit of these treatments, although one report suggests that a statistically significant effect is exerted only by clomiphene citrate. However, clomiphene has been shown to be problematic in the high doses used by women. 30 Furthermore, the gonadotropins and androgens may act primarily in an indirect manner, via stimulation of Sertoli and/or Leydig cell factors that affect the germinal epithelium directly.

 Accordingly, it is an object of the present invention to provide a method for increasing fertility of men with oligospermia using a fertility agent that causes direct stimulation of sperm production by local administration.

35 It is another object to provide a fertility agent to treat hypospermatogenesis that is both safe and efficacious.

 This object and other objects will be apparent to one of ordinary skill in the art.

Summary of the Invention

The present invention provides a method of increasing fertility in a male mammal exhibiting germinal epithelium failure comprising administering to the mammal an effective amount of activin.

5 In another aspect, the invention provides a pharmaceutical composition for increasing fertility in male mammals exhibiting germinal epithelium failure comprising an effective amount of activin in a pharmaceutically acceptable carrier.

Brief Description of the Drawings

Figure 1 shows graphs of the level of incorporation of 3H-thymidine after 24 hours, 48
10 hours and 72 hours of treatment of rat Sertoli and germ cell cocultures with added activin A (A, 100 ng/ml), added inhibin (I, 100 ng/ml), or control (C). All conditions contained medium plus 5F (which is insulin, 5 μ g/ml; transferrin, 5 μ g/ml; α -tocopherol, 5 μ g/ml; EGF, 5 ng/ml; and aprotinin, 25 μ g/ml).

Figure 2A shows a graph of DNA flow cytometric quantification of inhibin-treated rat
15 Sertoli and germ cell cocultures at 48 hours compared with a control (5F). Figure 2B shows a similar graph comparing activin treatment with a control (5F).

Description of the Preferred Embodiments

As used herein, the term "activin" refers to homo- or heterodimers of β chains of inhibin, prepro forms, and pro forms, together with glycosylation and/or amino acid sequence
20 variants thereof. After cleavage from the mature protein, the precursor portion may be non-covalently associated with the mature protein. Activin A refers to activin with the two chains of β_A . Activin AB refers to activin with the chains β_A and β_B . Activin B refers to activin with the two chains of β_B .

The intact isolated prepro or prodomain or mature β_A and β_B sequences are suitably
25 synthesized by any means, including synthetic and/or recombinant means, but are preferably synthesized in recombinant cell culture, for example, as described in U.S. Pat. No. 4,798,885 issued January 17, 1989.

It is within the scope hereof to employ activin from animals other than humans, for example, porcine or bovine sources, to treat humans. For example, the nucleotide and
30 deduced amino acid sequences of the porcine activin β chain are found in Figures 2A and 2B of U.S. Pat. No. 4,798,885, *supra*. Likewise, if it is desirable to treat other mammalian species such as domestic and farm animals and sports, zoo, or pet animals, human activin, as well as activin from other species, is suitably employed.

Generally, amino acid sequence variants will be substantially homologous with the
35 relevant portion of the mammalian β chain sequences set forth in, e.g., U.S. Pat. No. 4,798,885, *supra*. Substantially homologous means that greater than about 60% of the primary amino acid sequence of the homologous polypeptide corresponds to the sequence of the activin chain when aligned to maximize the number of amino acid residue matches

between the two proteins. Alignment to maximize matches of residues includes shifting the amino and/or carboxyl terminus, introducing gaps as required, and/or deleting residues present as inserts in the candidate. Typically, amino acid sequence variants will be greater than about 70% homologous with the corresponding native sequences.

5 While the site for introducing a sequence variation is predetermined, it is unnecessary that the mutation *per se* be predetermined. For example, in order to optimize the performance of mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed activin mutants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA
10 having a known sequence are well known, for example, M13 primer mutagenesis.

 Mutagenesis is conducted by making amino acid insertions, usually on the order of about from 1 to 10 amino acid residues, or deletions of about from 1 to 30 residues. Substitutions, deletions, insertions, or any subcombination may be combined to arrive at a final construct. Preferably, however, substitution mutagenesis is conducted. Obviously, the
15 mutations in the encoding DNA must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.

 Covalent modifications of activin are included within the scope of the invention, and include covalent or aggregative conjugates with other chemical moieties. Covalent
20 derivatives are prepared by linkage of functionalities to groups that are found in the activin amino acid side chains or at the N- or C-termini, by means known in the art. For example, these derivatives will include: aliphatic esters or amides of the carboxyl terminus or residues containing carboxyl side chains, e.g., aspartyl residues; O-acyl derivatives of hydroxyl group-containing residues such as aryl or alanyl; and N-acyl derivatives of the amino terminal amino
25 acid or amino-group containing residues, e.g., lysine or arginine. The acyl group is selected from the group of alkyl moieties (including C3 to C10 normal alkyl), thereby forming alkanoyl species, and carbocyclic or heterocyclic compounds, thereby forming aroyl species. The reactive groups preferably are difunctional compounds known *per se* for use in crosslinking proteins to insoluble matrices through reactive side groups, e.g., m-maleimidobenzoyl-N-
30 hydroxy succinimide ester. Preferred derivatization sites are at histidine residues.

 The expression "administering to the testis" means not only injection into the testis, but also techniques that result in flooding the area surrounding the testis with activin such that the activin is absorbed into the testis. In addition, the activin can be injected into a vessel that feeds the testis, preferably using a microscopic procedure. Furthermore, the
35 activin can be put into an implant that is placed near the testis and through which the activin is absorbed into the testis. Examples include an intratesticular long-acting depot (e.g., microsphere) or slow-release implant. Other techniques may be employed, provided that the

result is that activin is applied locally to the testis and is effective for the purposes stated herein.

The expression "germinal epithelium failure" refers to disorders of male mammals that may be characterized as complete or partial germinal epithelium failure, provided that some spermatogonal stem cells are present, as determined, e.g., by a testis biopsy analysis. Examples of such disorders include those characterized as partial germinal epithelium failure as well as azoospermia presenting in patients who have some spermatogonal stem cells. Complete failure is associated with high basal FSH levels.

The expression "partial germinal epithelium failure" refers to a disorder of mammals that present with oligospermia and intact Leydig cell steroidogenic capacity and pituitary cells. Such males have normal testosterone levels but low sperm counts. Most clinicians consider a sperm density of less than 20 million/ml with adequate volume, motility and morphology to indicate low sperm count. Sperm morphology is another indication, with one suggestion that low sperm count is evidence when the percentage of abnormal spermatozoa is above 40.

The disorders characterized as partial germinal epithelium failure may be caused by chemicals or drugs such as chemotherapeutic drugs and sulfa antibiotics, as well as alcohol and illicit drugs. Other possible causes include genetic disorders, genital tract infections, and varicoceles. The largest group of infertile men falls into the category of idiopathic oligospermia, without an evident etiology. The need for an increase in fertility is generally due to a primary testicular disorder, i.e., not at the hypothalamic or pituitary level.

The present invention concerns itself with using activin to increase fertility in male mammals in the patient population identified above, including sports, zoo, pet, and farm animals such as dogs, cats, cattle, pigs, horses, monkeys, and sheep, as well as humans. Preferably the disorder is partial germinal epithelium failure.

The activin is administered to the mammal by any suitable technique, including parenteral, sublingual, intratesticular, intrapulmonary, and intranasal administration. The specific route of administration will depend, e.g., on the medical history of the patient. Examples of parenteral administration include intramuscular, subcutaneous, intravenous, intraarterial, and intraperitoneal administration. Preferably, the activin is administered via the testis, as discussed above.

The activin compositions to be used in the therapy will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient, the site of delivery of the activin composition, the method of administration, the scheduling of administration, and other factors known to practitioners.

The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the activin administered per dose will be in the range of about 1 μ g/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to a great deal of therapeutic

discretion. Preferably, this dose is no more than about 10 $\mu\text{g/kg/day}$. The key factor in selecting an appropriate dose is the result obtained, as measured by increases in sperm density by serum analysis or the number of spermatocytes, or by other criteria as deemed appropriate by the practitioner, e.g., biopsy.

5 For administration, the activin is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other
10 compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the activin uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such
15 carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, nitrate, and
20 other organic acid salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose,
25 mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium, and/or nonionic surfactants such as Tween, Pluronic, or PEG.

The activin is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml at physiological pH. It will be understood that use of certain of the
30 foregoing excipients, carriers, or stabilizers will result in the formation of activin salts.

Activin to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).

Therapeutic activin compositions generally are placed into a container having a sterile access port, for example, a vial having a stopper pierceable by a hypodermic injection needle.

35 Activin ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous activin solution, and the resulting mixture is lyophilized. The infusion

solution is prepared by reconstituting the lyophilized activin using 5 ml of sterile water or Ringer's solution.

The activin is also suitably administered by sustained release systems. Suitable examples of sustained release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (U. Sidman *et al.*, Biopolymers, 22, 547-556 (1983)), poly(2-hydroxyethyl methacrylate) (R. Langer *et al.*, J. Biomed. Mater. Res., 15: 167-277 (1981), and R. Langer, Chem. Tech., 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer *et al.*, Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained release activin compositions also include liposomally entrapped activin. Liposomes containing activin are prepared by methods known *per se*: DE 3,218,121; Epstein *et al.*, Proc. Natl. Acad. Sci. U.S.A., 82: 3688-3692 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. U.S.A., 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appln. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal activin therapy.

Activin therapy is suitably combined with other proposed or conventional fertility increasing therapies. For example, activin can be administered with other fertility agents used to stimulate proliferation and differentiation of germ cells.

Examples of other therapies or agents include induction of rebound from testosterone or anabolic androgen-induced azospermia; administration of exogenous gonadotropins or gonadotropin releasing factors such as human chorionic gonadotropin (hCG), human menopausal gonadotropin (hMG), purified FSH, or gonadotropin releasing hormone (GnRH). Alternatively, clomiphene citrate or tamoxifen may be used in conjunction with activin to stimulate endogenous gonadotropin secretion. In addition, low doses of mesterolone, an oral synthetic androgen, or an aromatase inhibitor such as testolactone may be administered.

The inhibin and fertility agents are suitably delivered by separate or the same means, by separate or the same administration route, and at the same or at different times, depending, e.g., on dosing, the clinical condition of the patient, etc. It is not necessary that such fertility agents be included in the activin compositions *per se*, although this will be convenient where such drugs are delivered by the same administration route.

When employed together with the activin, such agents typically are employed in lesser dosages than when used alone. If hCG is used, preferably the effective amount is 1500 to 2000 I.U. twice weekly until testosterone levels are in the adult male range. At that point, hMG in a dose of about one ampule every other day is also administered. If clomiphene citrate therapy is employed, treatment is typically 25 mg of clomiphene citrate daily for 21

-10-

to 25 days, followed by a 5- to 7-day rest period. This cycle is generally repeated for at least 24 weeks.

A typical combined composition will contain the above-noted amount of activin and about 25 mg of clomiphene citrate in a suitable intraperitoneal fluid such as lactated Ringer's solution.

The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

EXAMPLE I

Sertoli cells and germ cells from 20-day-old male Sprague-Dawley rats (Charles River Laboratories, Inc., Wilmington, MA) were co-cultured in serum-free media. Cultures were prepared according to the glycine/collagenase method described by Mather and Phillips in Methods for Serum-Free Culture of Cells of the Endocrine System, Barnes and Sato eds. (Alan R. Liss, Inc.: New York, 1984), p. 29-45, and Rich *et al.*, Endocrinol., **113**: 2284-2293 (1983).

Briefly, testis were removed and decapsulated and the tubules teased apart in a hypertonic glycine solution. The return of the tubules to isoosmotic medium results in lysis of the interstitial tissue without harming the tubules. The tubules were then minced into smaller segments and enzymatically treated with collagenase/dispase to remove the basement membranes and peritubular cells. The peritubular cells were discarded and the tubular pieces of 1-5 mm in length, which contain Sertoli cells and spermatogonia and spermatocytes, were plated in serum-free Ham's F12/DME medium supplemented with HEPES and insulin, 5 μ g/ml; transferrin, 5 μ g/ml; α -tocopherol, 5 μ g/ml; epidermal growth factor (EGF), 5ng/ml; and aprotinin, 25 μ g/ml (5F). After 20-24 hours the Sertoli cells had attached to the substrate and spread to form a monolayer. Spermatocytes could be seen adhering to the monolayer as single cells or groups of two cells or floating unattached in the medium.

At 24 hours after plating the medium was changed and unattached cells were discarded. Fresh 5F medium was added to all cultures, and additionally 100 ng/ml human recombinant inhibin A or activin A (prepared and purified as described in U.S. Pat. No. 4,798,885 issued January 17, 1989) was added to the experimental conditions. All conditions were assayed in triplicate and the entire experiment was repeated multiple (>10) times.

Between 24 and 48 hours of treatment, clusters of spermatogonia and increased numbers of primary spermatocytes appeared in the activin-treated wells. These cells appear as connected clusters of 8-32 cells attached to the Sertoli cell monolayer and large cells in suspension. No such effect was seen with inhibin.

Each well contained 2 million cells. A total of 1 μ Ci of 3H-thymidine was added to each well after 24, 48, or 72 hours of treatment with activin or inhibin.

Label incorporation into cells was measured after 20 hours of incubation with 3H-thymidine. Cells were detached from the substrate by vigorous pipetting with a 1 ml Pipettman™ pipettor, and the entire contents of the well was transferred to a 10-ml filter well containing two glass fiber filters and 5 ml of cold 20% trichloroacetic acid. The precipitated
5 cells were caught on the filter and washed two times with cold 5% trichloroacetic acid to remove unincorporated 3H-thymidine. Filters were washed once with cold methanol and counted in a scintillation fluid appropriate for aqueous samples.

The results are shown in Figure 1. Incorporation was higher in the activin-treated wells compared with untreated control or inhibin-treated wells in all cases. At 48 hours of culturing
10 the activin was at its highest incorporation ($11,040 \text{ cpm} \pm 1572 \text{ SEM}$) relative to the control (4515 ± 597) and inhibin-treated cultures (5355 ± 466). Thus, activin increases the proliferation of the spermatocytes.

The effect of inhibin and activin on germ cell differentiation was quantified by flow cytometric analysis. Sertoli cells were stained with Nile red (a selective fluorescent stain for
15 intracellular lipid droplets) and non-staining germ cells were electronically gated. A DNA-specific fluorochrome (Hoechst 33342) was used to determine the percentage of germ cells with N, 2N or 4N DNA content, with 4N = primary spermatocytes. As seen from Figures 2A and 2B, activin-treated cultures had a significant increase in the percentage of 4N germ cells as compared with control or inhibin-treated cultures at 48 hours.

20 In conclusion, activin stimulates the proliferation and differentiation of 20-day old rat testicular germ cells *in vitro*, indicating that it will increase fertility in the male. The data also indicate that local administration of activin, being mitogenic for germ cells via, e.g., an intratesticular depot method, would cause direct gonadal stimulation of sperm production, independent of (or possibly in concert with) changes in gonadotropin secretion.

WHAT IS CLAIMED IS:

1. A method of increasing fertility in a male mammal exhibiting germinal epithelium failure comprising administering to the mammal an effective amount of activin.
2. The method of claim 1 wherein the activin is porcine or human activin A, activin AB, or activin B.
3. The method of claim 2 wherein the activin is human activin A.
4. The method of claim 1 wherein the administration is to the testis.
5. The method of claim 4 wherein the administration is by injection into the testis.
6. The method of claim 1 wherein the mammal is human.
7. The method of claim 1 wherein the effective amount is a daily dose of about 1 $\mu\text{g/kg}$ to 10 mg/kg .
8. The method of claim 1 wherein the germinal epithelium failure is partial germinal epithelium failure.
9. A pharmaceutical composition for increasing fertility in male mammals exhibiting germinal epithelium failure comprising an effective amount of activin in a pharmaceutically acceptable carrier.
10. The composition of claim 9 wherein the activin is porcine or human activin A, activin AB, or activin B.
11. The composition of claim 10 that contains human activin A.
12. The composition of claim 9 wherein the carrier is sterile water, a buffer, or Ringer's solution.




FIG. 2A





FIG. 2B



INTERNATIONAL SEARCH REPORT

International Application No PCT/US 91/00074

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : A 61 K 37/43										
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px; vertical-align: top;">IPC⁵</td> <td style="padding: 5px; vertical-align: top;">A 61 K, C 07 K</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black; margin: 5px 0;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸</div>			Classification System	Classification Symbols	IPC ⁵	A 61 K, C 07 K				
Classification System	Classification Symbols									
IPC ⁵	A 61 K, C 07 K									
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ¹⁰</th> <th style="width: 70%; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 20%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px; vertical-align: top; text-align: center;">A</td> <td style="border-right: 1px solid black; padding: 5px; vertical-align: top;"> US, A, 4864019 (WYLIE W. VALE et al.) 5 September 1989 ----- </td> <td style="border-right: 1px solid black; padding: 5px; vertical-align: top;"></td> </tr> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	US, A, 4864019 (WYLIE W. VALE et al.) 5 September 1989 -----			
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³								
A	US, A, 4864019 (WYLIE W. VALE et al.) 5 September 1989 -----									
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>										
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px; text-align: center;">16th April 1991</td> <td style="border-bottom: 1px solid black; padding: 5px; text-align: center;">30.05.91</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px; text-align: center;">EUROPEAN PATENT OFFICE</td> <td style="padding: 5px;"> Danielle van der Haas </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	16th April 1991	30.05.91	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	Danielle van der Haas
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report									
16th April 1991	30.05.91									
International Searching Authority	Signature of Authorized Officer									
EUROPEAN PATENT OFFICE	Danielle van der Haas									

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 1, 8, because they relate to subject matter not required to be searched by this Authority, namely:

Please see Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This international searching authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the international searching authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9100074

SA 44281

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 27/05/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4864019	05-09-89	None	

EPO FORM P009

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.